IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3619
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$11M
Lewis H. Bender
Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our principal executive offices are located at 61 Wilton Road, 3rd Floor, Westport, CT.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$INTS INTENSITY THERAPEUTICS, INC. | 39 | 19 | 8 | 50 | - | - | -167.1% | -125.9% | - | - | - | - | 0.0% | 33.0x | $11M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
INTENSITY THERAPEUTICS, INC. (INTS) receives a "Avoid" rating with a composite score of 39.4/100. It ranks #3619 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Lewis H. Bender
Chief Executive Officer
Labor Force
2
19
25
27
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for INTS
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for INTS.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -167.1% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 3yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags INTENSITY THERAPEUTICS, INC. with an Avoid rating, assigning a composite score of 39.4/100 and 1 out of 5 stars. Ranked #3619 of 7,333 stocks, INTS falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
INTENSITY THERAPEUTICS, INC. registers a weak quality score of just 19/100, indicating significant profitability challenges. The company reports a return on equity of -167.1% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
INTS registers a value score of just 8/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.95x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
INTENSITY THERAPEUTICS, INC.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -125.9% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
INTS demonstrates moderate momentum with a score of 50/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of -3.35 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
INTS's stability score of 27/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -3.35 and a debt-to-equity ratio of 33.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
INTS's short interest factor score of 86/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 33.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $11M, INTENSITY THERAPEUTICS, INC. benefits from the generally lower volatility and deeper liquidity associated with its size class.
INTENSITY THERAPEUTICS, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3619 of 7,333 overall (51st percentile). Key comparisons include ROE of -167.1% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While INTS currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (8) would have the largest impact on the composite score.
ROE 6638% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 16400% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate INTENSITY THERAPEUTICS, INC. (INTS) as Avoid with a composite score of 39.4/100 at a current price of $6.81. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (50th percentile) and stability (27th percentile), which together account for the majority of the composite score. Offsetting weakness in value (8th percentile) and quality (19th percentile) tempers our overall conviction. We assign a No Moat rating (21/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
INTENSITY THERAPEUTICS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.4/100 places it at rank #3619 in our full 7,333-stock universe. At $11M in market capitalization, INTENSITY THERAPEUTICS, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (50th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for INTENSITY THERAPEUTICS, INC., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $6.81, INTENSITY THERAPEUTICS, INC. is trading at a premium to fundamental value. Our value factor score of 8/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 1.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 39.4/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (19th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Elevated short interest (86th percentile) indicates that sophisticated market participants are betting against the stock.
We assign a Medium uncertainty rating to INTENSITY THERAPEUTICS, INC.. The stock presents a balanced risk profile: below-average price stability (27th percentile) and weak quality scores (19th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: below-average price stability (27th percentile); weak quality scores (19th percentile); low beta of -3.35 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 27th percentile and quality factor at the 19th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our medium uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate INTENSITY THERAPEUTICS, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-167.1%), weak asset returns (ROA -125.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — INTENSITY THERAPEUTICS, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, INTENSITY THERAPEUTICS, INC. receives a Avoid rating with a composite score of 39.4/100 (rank #3619 of 7,333). Our quantitative framework assigns a No Moat (21/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 26/100.
Our analysis does not support a constructive view on INTENSITY THERAPEUTICS, INC. at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign INTENSITY THERAPEUTICS, INC. a meaningful economic moat, scoring 21/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (8.3/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of INTENSITY THERAPEUTICS, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect INTENSITY THERAPEUTICS, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 19/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -167.1% and ROA of -125.9%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -167.1% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 33%. The sector median D/E is 0%, putting INTENSITY THERAPEUTICS, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Intensity Therapeutics (NASDAQ:INTS) has announced a 1-for-25 reverse stock split to increase its share price and comply with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 63.3 million to 2.5 million, with trading on a split-adjusted basis beginning February 19, 2026. The company also recently detailed its 2026 strategic priorities, including clinical development for INT230-6 and an expanded at-the-market offering program.
Intensity Therapeutics Inc. (NASDAQ: INTS) saw its stock jump 7.1% in premarket trading after securing a 180-day extension from Nasdaq to regain compliance with the exchange's minimum bid price requirement. The company now has until June 1, 2026, to maintain a closing bid price of at least $1.00 per share for ten consecutive business days. This extension prevents an immediate impact on the trading of its shares on the Nasdaq Capital Market.
Intensity Therapeutics (Nasdaq: INTS) announced the publication of Phase 1/2 clinical results for its investigational product INT230-6 in metastatic or refractory solid tumors in eBioMedicine, a Lancet Discovery Science journal. The study demonstrated a 75% disease control rate and an overall median survival of 11.9 months, with a sarcoma subset showing a median overall survival of 21.3 months. Results also highlighted favorable safety, with no dose-limiting toxicities and over 95% of active agents remaining in injected tumors.
Benchmark has reduced its price target for Intensity Therapeutics (NASDAQ: INTS) to $1.50 from $4.00, citing recent share dilution despite maintaining a positive outlook and a Speculative Buy rating. The company's stock has declined over 93% in the past year, currently trading at $0.29. Intensity Therapeutics reported improved Q2 2025 financial results with a reduced net loss and promising early data from its late-stage clinical trials.
Intensity Therapeutics (Nasdaq: INTS) successfully raised $6.6 million in gross proceeds through an At-the-Market (ATM) offering in July 2025, selling 19.9 million shares at a 10% premium to its June 2025 public offering price. This funding extends the company's cash runway into the second half of 2026, supporting the advancement of its clinical trials for novel intratumoral cancer therapies. Following the ATM sales, Intensity Therapeutics reported a total of 46 million outstanding common shares as of July 31, 2025.